pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update
The July 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are:
- 9 negotiations were completed, while none were closed for a total of 228 completed/closed negotiations;
- 8 new drug products have initiated pCPA negotiations, for a total of 46 active negotiations;
- No new drug products were added to the “No pCPA Negotiations” list, for a total of 59 products for which the pCPA has declined to negotiate – collectively or at the provincial-territorial level.
- 8 new drug products have initiated pCPA negotiations since the last update, for a total of 46 active negotiations
|Brand Name||Generic Name||Manufacturer||Indication||Recommendation/
Notification to Implement Date
|Time to Initiation*|
|Actemra||Tocilizumab||Hoffman-La Roche Limited||Giant cell arteritis (GCA)||March 27, 2018||110 days|
|Bavencio||Avelumab||EMD Serono – Pfizer Alliance||Metastatic Merkel Cell Carcinoma||April 6, 2018||100 days|
|Lartruvo||Olaratumab||Eli Lilly Canada Inc.||Advanced soft tissue sarcoma (STS)||May 3, 2018||73 days|
|Lixiana||edoxaban||Daiichi Sankyo, Inc||Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism||March 21, 2017||481 days|
|Lixiana||edoxaban||Daiichi Sankyo, Inc||venous thromboembolism, treatment and recurrence prevention||May 25, 2017||416 days|
|Ocrevus||ocrelizumab||Hoffman-La Roche Limited||Multiple Sclerosis, relapsing||November 21, 2017||236 days|
|Ocrevus||ocrelizumab||Hoffman-La Roche Limited||Primary progressive multiple sclerosis||April 26, 2018||80 days|
|Tecentriq||atezolizumab||Hoffman-La Roche Limited||Non-small cell lung cancer||July 6, 2018||9 days|
*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation
For the second consecutive month, the pCPA has initiated 8 negotiations. All the files initiated in July are for new drugs or indications, associated with HTA recommendations that had not yet been actioned by the pCPA. This is the first month since January 2018 that no “pCPA-initiated” files or re-negotiations have been initiated. While the Lixiana indications have been under pCPA consideration for well over a year, negotiations for Tecentriq were initiated in the same month in which the HTA recommendation was issued.
- 9 negotiations were completed since the last update, for a total of 202 completed negotiations.
|Brand Name||Generic Name||Manufacturer||Indication||Negotiation Initiation||Duration *|
|Dysport Therapeutic||Abobotulinumtoxin A||IPSEN Biopharmaceuticals Canada, Inc.||Cervical dystonia||May 2018||61 days|
|Dysport Therapeutic||Abobotulinumtoxin A||IPSEN Biopharmaceuticals Canada, Inc.||Upper limb spasticity||May, 2018||61 days|
|Hemangiol||Propranolol||Pierre Fabre Dermo-Cosmétique||Infantile hemangioma||August, 2017||334 days|
|Pomalyst**||Pomalidomide||Celgene Inc.||Multiple Myeloma||March, 2018||122 days|
|Procysbi||Cysteamine bitartrate||Horizon Therapeutics Canada||Nephropathic cystinosis||February, 2018||150 days|
|Renflexis||Infliximab||Merck Canada Inc.||Inflammatory Conditions||April, 2018||91 days|
|Rydapt||Midostaurin||Novartis Pharmaceuticals Canada Inc.||Acute myeloid leukemia||February, 2018||150 days|
|Tagrisso||Osimertinib||Astra Zeneca Canada Inc||locally advanced or metastatic EGFR T790M mutationpositive non-small cell lung cancer (NSCLC) who have progressed on or after EGFR TKI therapy||September, 2017||303 days|
|Tresiba||Insulin degludec||Novo Nordisk Canada Inc.||Type 1 and Type 2 diabetes||April, 2018||91 days|
*Approximation: Negotiation initiation and completion date assumed to be mid-month for the purposes of the calculation
** 2nd letter of intent, the first was completed in January 2015
- No negotiations were closed since the last update, for a total of 26 closed negotiations.
Of note, July saw the pCPA complete negotiations on the second infliximab biosimilar (Renflexis) as well as the first addition to the “long-acting insulin” category since the completion of the Basaglar (insulin glargine biosimilar) negotiation.
Files Under pCPA Consideration
In addition to the monthly updates to the pCPA website, MORSE Consulting tracks the number of products “under pCPA Consideration” which have been reviewed by CADTH but have not yet been initiated for negotiation or closed without negotiations.
- Four new drug products received a CDEC or pERC recommendation or notification to implement in June 2018, for a total of approximately 26 products under pCPA Consideration.
|Brand Name||Generic Name||Manufacturer||Indication||Final Recommendation/
Notification to Implement
|Besponsa||Inotuzumab ozogamicin||Pfizer Canada Inc.||Leukemia Acute Lymphoblastic Leukemia (ALL)||Reimburse conditional on cost-effectiveness being improved to an acceptable level|
|Lonsurf||Trifluridine and tipiracil||Taiho Pharma Canada Inc.||Metastatic Colorectal Cancer||Does not recommend reimbursement|
|Janssen Inc.||HIV 1 Infection||Reimburse with clinical criteria and/or conditions|
|Tecentriq||Atezolizumab||Hoffman-La Roche Limited||Non-small cell lung cancer||Reimburse conditional on cost-effectiveness being improved and that the drug plan cost should not exceed the public drug plan cost of treatment with the least costly alternative immunotherapy|
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.